| Project Detail |
TILT Biotherapeutics is developing a breakthrough oncolytic immunotherapy treatment for cancer. Advanced solid tumors are currently incurable and limited treatment options are available – preclinical data on TILT technology suggests curative potential. There are 8 million people dying from cancer each year and the incidence is growing rapidly. New immunotherapies for cancer are more widely available in America than in Europe partly because clinical research concentration in the U.S. Cancer patients also in Europe are in the increasing need of new treatment options.
The objective of this project is to generate a clinical proof-of-concept for the company’s lead product, TILT-123, given with anti-PD1 therapy in metastatic melanoma and other advanced solid tumors by completing a Phase I clinical trial. This project will last in total about 2 years and allow the company to confirm safety in human for TILT-123 with anti-PD1 treatment, as well as to generate mechanism of action data. Eventually, this could result in improved treatment responses in currently incurable anti-PD1 refractory patients with melanoma and other solid tumor types.
TILT-123 is currently in late preclinical stage with all the key proof-of-concept and safety already demonstrated. Pilot product production is ongoing and the Phase I clinical trial is set to begin 2018. EU support would be critical to launch this project onto clinical path. Actors from at least five different European countries would be involved, underlining project’s EU-wide relevance. From the business perspective, this project would allow the company to mature into a stage from where its further development could be privately funded and supported by a pharmaceutical company. TILT Biotherapeutics will invest into further development of its pipeline projects, create more employment and business locally in Finland and Europe, and to bring an innovative treatment option with curative potential to the reach of European cancer patients. |
